Literature DB >> 21136234

[Comparison of risk factors and guideline oriented prevention and therapy of diabetic retinopathy between type 2 diabetes patients undergoing laser therapy and type 2 diabetes outpatients].

Ralf Paschke1, Florian Gerhard Wuthe, Katja Kühn, Claudia Jochmann, Peter Wiedemann.   

Abstract

PURPOSE: The purpose of this study was the comparison of risk factors for development or progression of diabetic retinopathy in patients with type 2 diabetes between patients of a laser therapy center and a diabetes outpatient clinic. Furthermore, the implementation of the guidelines of the German Diabetic Association for the prevention and therapy of diabetic retinopathy was analysed. PATIENTS AND METHODS: In a prospective study, patients with type 2 diabetes and diabetic retinopathy of the laser therapy center at the ophthalmology department, Leipzig University, were interviewed and examined. Patients of the reference group without diabetic retinopathy were recruited from the diabetes outpatient clinic Leipzig University.
RESULTS: Between August 2004 and May 2008, a total of 180 patients with type 2 diabetes were included (48 patients with non-proliferative diabetic retinopathy (NPDR), 59 patients with proliferative diabetic retinopathy (PDR) and 73 patients belonging to the reference group). Patients with diabetic retinopathy had significantly higher mean blood pressures of 112 and 110 mmHg as compared to patients without diabetic retinopathy (96 mmHg). ACE/ AT1-inhibitors were used significantly less by patients with as compared to patients without diabetic retinopathy. Only 37% of patients with diabetic retinopathy were treated according to DDG and ADA guidelines.
CONCLUSION: There are striking deficits for the implementation of guideline oriented prevention and therapy of diabetic retinopathy in daily practice. The possible reasons are insufficient compliance of patients who consulted medical advice only when complications of diabetes occurred, the necessary improvement of the medical therapy and the suboptimal cooperation between ophthalmology and diabetes specialists.

Entities:  

Mesh:

Year:  2010        PMID: 21136234     DOI: 10.1007/s00063-010-1131-6

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  33 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Diabetes: from phenotypes to genotypes.

Authors:  P J Guillausseau; D Tielmans; M Virally-Monod; M Assayag
Journal:  Diabetes Metab       Date:  1997-03       Impact factor: 6.041

3.  Association of ocular disease and mortality in a diabetic population.

Authors:  R Klein; B E Klein; S E Moss; K J Cruickshanks
Journal:  Arch Ophthalmol       Date:  1999-11

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Authors:  Anthony H Barnett; Stephen C Bain; Paul Bouter; Bengt Karlberg; Sten Madsbad; Jak Jervell; Jukka Mustonen
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

6.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.

Authors: 
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

9.  Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.

Authors:  Ying Wang; Maggie C Y Ng; Shao-Chin Lee; Wing-Yee So; Peter C Y Tong; Clive S Cockram; Julian A J H Critchley; Juliana C N Chan
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

10.  Genome-wide scans for diabetic nephropathy and albuminuria in multiethnic populations: the family investigation of nephropathy and diabetes (FIND).

Authors:  Sudha K Iyengar; Hanna E Abboud; Katrina A B Goddard; Mohammed F Saad; Sharon G Adler; Nedal H Arar; Donald W Bowden; Ravi Duggirala; Robert C Elston; Robert L Hanson; Eli Ipp; W H Linda Kao; Paul L Kimmel; Michael J Klag; William C Knowler; Lucy A Meoni; Robert G Nelson; Susanne B Nicholas; Madeleine V Pahl; Rulan S Parekh; Shannon R E Quade; Stephen S Rich; Jerome I Rotter; Marina Scavini; Jeffrey R Schelling; John R Sedor; Ashwini R Sehgal; Vallabh O Shah; Michael W Smith; Kent D Taylor; Cheryl A Winkler; Philip G Zager; Barry I Freedman
Journal:  Diabetes       Date:  2007-03-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.